•Levi & Korsinsky initiated a securities fraud investigation into Fulcrum Therapeutics after its stock fell 50% following FDA safety concerns regarding PRC2 inhibition.
•Shake Shack is facing a legal probe after abruptly cutting its Q2 2026 same-store sales growth projections from 3-5% to 2.5-3%.
